FINWIRES · TerminalLIVE
FINWIRES

Wedbush表示，儘管預期有所下調，但藝電交易仍按計劃進行。

By

-- Wedbush週三在一份報告中指出，藝電(EA)似乎正按計劃完成其待定交易，而在線服務業務的增長、利潤率的提升以及《FC》、《麥登橄欖球》和《Apex英雄》等穩定係列遊戲的持續表現，將支撐其未來的業績。 這家投資公司下調了2027財年和2028財年的業績預測，因為目前預期線上服務業務的貢獻將更為謹慎，主要來自《戰地6》的玩家群。同時，Wedbush將2027財年的淨預訂量預期從83.5億美元下調至80.7億美元，每股收益預期從9.41美元下調至8.73美元。 對於2028財年，Wedbush將淨預訂量預期從85.5億美元下調至82.9億美元，每股盈餘預期從9.90美元下調至9.27美元。但該公司補充說，由於新遊戲發布相關支出減少以及研發、銷售和行銷方面的槓桿作用增強，其仍預計2027財年的營業利潤率將有所提高。 預計到 2027 財年，線上服務業務將成長約 9%，佔總預訂量的 76% 左右，主要得益於《Apex 英雄》、《全球足球》以及其他持續營運的遊戲系列。 Wedbush 維持對 Electronic Arts 的「中性」評級和 210 美元的目標價，並表示該目標價已反映了已公佈的交易價格。

Price: $201.66, Change: $+0.09, Percent Change: +0.04%

Related Articles

Australia

Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says

Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%

$APTV$F
Research

Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target

Price: $15.79, Change: $-4.34, Percent Change: -21.55%

$CRTO
Australia

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%

$OCUL